Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

A.K.M. Claessens; J.J.V. Busschbach; B.L.T. Ramaekers; F.L.G. Erdkamp; J.M. Bouma; A.E. van Leeuwen-Stok; V.C.G. Tjan-Heijnen; M.E.M.M. Bos; Dutch Breast Cancer Research Group (BOOG)

doi:10.1080/0284186x.2022.2033832

Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

A.K.M. Claessens, J.J.V. Busschbach, B.L.T. Ramaekers, F.L.G. Erdkamp, J.M. Bouma, A.E. van Leeuwen-Stok, V.C.G. Tjan-Heijnen, M.E.M.M. Bos^*, Dutch Breast Cancer Research Group (BOOG)

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	619-624
Number of pages	6
Journal	Acta Oncologica
Volume	61
Issue number	5
Early online date	8 Feb 2022
DOIs	https://doi.org/10.1080/0284186x.2022.2033832
Publication status	Published - 4 May 2022

Keywords

HEALTH
BEVACIZUMAB
BURDEN
STATES
CARE
US

Access to Document

10.1080/0284186x.2022.2033832

Cite this

Claessens, A. K. M., Busschbach, J. J. V., Ramaekers, B. L. T., Erdkamp, F. L. G., Bouma, J. M., van Leeuwen-Stok, A. E., Tjan-Heijnen, V. C. G., Bos, M. E. M. M., & Dutch Breast Cancer Research Group (BOOG) (2022). Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer. Acta Oncologica, 61(5), 619-624. https://doi.org/10.1080/0284186x.2022.2033832

@article{da05a232df4b4dc9811d960b6666c146,

title = "Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer",

keywords = "HEALTH, BEVACIZUMAB, BURDEN, STATES, CARE, US",

author = "A.K.M. Claessens and J.J.V. Busschbach and B.L.T. Ramaekers and F.L.G. Erdkamp and J.M. Bouma and {van Leeuwen-Stok}, A.E. and V.C.G. Tjan-Heijnen and M.E.M.M. Bos and {Dutch Breast Cancer Research Group (BOOG)}",

note = "Funding Information: This study was funded by F. Hoffmann-La Roche Ltd, the Netherlands and TEVA Nederland B.V. These companies had no input in the design and/or analysis of this cost-effectiveness study. We thank all patients, physicians (research)nurses and local data managers who participated in the Stop&Go trial; the members of the steering committee, the data safety monitoring committee, the central data management from the Comprehensive Cancer Centre the Netherlands, especially Steffen de Groot; and the Dutch Breast Cancer Research Group. We thank the teams from F. Hoffmann-La Roche Ltd and TEVA Nederland B.V. for their support.",

year = "2022",

month = may,

day = "4",

doi = "10.1080/0284186x.2022.2033832",

language = "English",

volume = "61",

pages = "619--624",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Routledge/Taylor & Francis Group",

number = "5",

}

Claessens, AKM, Busschbach, JJV, Ramaekers, BLT, Erdkamp, FLG, Bouma, JM, van Leeuwen-Stok, AE, Tjan-Heijnen, VCG, Bos, MEMM & Dutch Breast Cancer Research Group (BOOG) 2022, 'Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer', Acta Oncologica, vol. 61, no. 5, pp. 619-624. https://doi.org/10.1080/0284186x.2022.2033832

TY - JOUR

T1 - Cost-effectiveness of continuous versus intermittent chemotherapy for patients with HER2-negative advanced breast cancer

AU - Claessens, A.K.M.

AU - Busschbach, J.J.V.

AU - Ramaekers, B.L.T.

AU - Erdkamp, F.L.G.

AU - Bouma, J.M.

AU - van Leeuwen-Stok, A.E.

AU - Tjan-Heijnen, V.C.G.

AU - Bos, M.E.M.M.

AU - Dutch Breast Cancer Research Group (BOOG)

N1 - Funding Information: This study was funded by F. Hoffmann-La Roche Ltd, the Netherlands and TEVA Nederland B.V. These companies had no input in the design and/or analysis of this cost-effectiveness study. We thank all patients, physicians (research)nurses and local data managers who participated in the Stop&Go trial; the members of the steering committee, the data safety monitoring committee, the central data management from the Comprehensive Cancer Centre the Netherlands, especially Steffen de Groot; and the Dutch Breast Cancer Research Group. We thank the teams from F. Hoffmann-La Roche Ltd and TEVA Nederland B.V. for their support.

PY - 2022/5/4

Y1 - 2022/5/4

KW - HEALTH

KW - BEVACIZUMAB

KW - BURDEN

KW - STATES

KW - CARE

KW - US

U2 - 10.1080/0284186x.2022.2033832

DO - 10.1080/0284186x.2022.2033832

M3 - Comment/Letter to the editor

C2 - 35139727

SN - 0284-186X

VL - 61

SP - 619

EP - 624

JO - Acta Oncologica

JF - Acta Oncologica

IS - 5

ER -